ES2283012T3
(en)
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
HELICOBACTER PYLORI BACTERIOFERRITINE.
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
CA2340330A1
(en)
|
1998-08-20 |
2000-03-02 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
|
WO2000011180A1
(en)
|
1998-08-20 |
2000-03-02 |
Connaught Laboratories Limited |
NUCLEIC ACID MOLECULES ENCODING POMP91A PROTEIN OF $i(CHLAMYDIA)
|
US6649370B1
(en)
|
1998-10-28 |
2003-11-18 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US6607730B1
(en)
|
1998-11-02 |
2003-08-19 |
Aventis Pasteur Limited/Aventis Pasteur Limitee |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
JP2002531093A
(en)
|
1998-12-01 |
2002-09-24 |
アベンティス、パストゥール、リミテッド |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
EP1144642B1
(en)
|
1998-12-08 |
2010-05-26 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US20020061848A1
(en)
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
GB9828000D0
(en)
|
1998-12-18 |
1999-02-10 |
Chiron Spa |
Antigens
|
EP1140999A1
(en)
|
1998-12-23 |
2001-10-10 |
Aventis Pasteur Limited |
$i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
|
US7297341B1
(en)
|
1998-12-23 |
2007-11-20 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US6808713B1
(en)
|
1998-12-28 |
2004-10-26 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
DE69938059T2
(en)
|
1998-12-28 |
2009-01-08 |
Sanofi Pasteur Ltd., Toronto |
CHLAMYDIA ANTIGENE, CORRESPONDING DNA FRAGMENTS AND ITS USES
|
GB9902555D0
(en)
|
1999-02-05 |
1999-03-24 |
Neutec Pharma Plc |
Medicament
|
EP1163342B1
(en)
|
1999-03-12 |
2008-12-10 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
CA2370441A1
(en)
*
|
1999-03-26 |
2000-10-05 |
Craig A. Rosen |
50 human secreted proteins
|
CA2368374A1
(en)
*
|
1999-03-26 |
2000-10-05 |
Human Genome Sciences, Inc. |
47 human secreted proteins
|
WO2000066739A2
(en)
|
1999-05-03 |
2000-11-09 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
NZ517952A
(en)
|
1999-09-20 |
2004-01-30 |
Aventis Pasteur |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US6632663B1
(en)
|
1999-09-22 |
2003-10-14 |
Aventis Pasteur Limited |
DNA immunization against chlamydia infection
|
NZ520200A
(en)
|
1999-12-22 |
2004-04-30 |
Aventis Pasteur |
Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product
|
EP1278855B1
(en)
|
2000-04-21 |
2008-03-12 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
EP1282718B1
(en)
|
2000-05-08 |
2006-12-20 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
ATE440861T1
(en)
|
2000-07-03 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE
|
US7537772B1
(en)
|
2000-10-02 |
2009-05-26 |
Emergent Product Development Gaithersburg Inc. |
Chlamydia protein, gene sequence and the uses thereof
|
US7731980B2
(en)
|
2000-10-02 |
2010-06-08 |
Emergent Product Development Gaithersburg Inc. |
Chlamydia PMP proteins, gene sequences and uses thereof
|
MXPA03003690A
(en)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a b.
|
US20030059896A1
(en)
*
|
2000-12-21 |
2003-03-27 |
Shire Biochem Inc. |
Novel chlamydia antigens and corresponding DNA fragments
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
NZ562929A
(en)
|
2001-12-12 |
2009-07-31 |
Novartis Vaccines & Diagnostic |
Immunisation against chlamydia trachomatis
|
GB0203403D0
(en)
|
2002-02-13 |
2002-04-03 |
Chiron Spa |
Chlamydia cytotoxic-T cell epitopes
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
DK2395073T3
(en)
|
2002-11-01 |
2017-10-23 |
Glaxosmithkline Biologicals Sa |
Process for drying.
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
JP2008504292A
(en)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
Immune enhancement compounds
|
EP1784211A4
(en)
|
2004-07-29 |
2010-06-30 |
Novartis Vaccines & Diagnostic |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
CN101203529A
(en)
|
2005-02-18 |
2008-06-18 |
诺华疫苗和诊断公司 |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
SG160329A1
(en)
|
2005-02-18 |
2010-04-29 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
JP2009511636A
(en)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
Mucosal and systemic immunity with alphavirus replicon particles
|
JP5215865B2
(en)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
Norovirus and sapovirus antigens
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2064230A2
(en)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immunogens from uropathogenic escherichia coli
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
RU2471497C2
(en)
|
2007-09-12 |
2013-01-10 |
Новартис Аг |
Mutant antigens gas57 and gas57 antibodies
|
WO2009081274A2
(en)
|
2007-12-21 |
2009-07-02 |
Novartis Ag |
Mutant forms of streptolysin o
|
DK2349520T3
(en)
|
2008-10-27 |
2016-08-15 |
Glaxosmithkline Biologicals Sa |
Purification Procedure for Group A Streptococcus Carbohydrate
|
CA2781805A1
(en)
*
|
2008-12-17 |
2010-07-08 |
Genocea Biosciences, Inc. |
Chlamydia antigens and uses thereof
|
BRPI1005670A8
(en)
|
2009-01-05 |
2017-12-26 |
Epitogenesis Inc |
adjuvant compositions and processes of use.
|
CA2749367A1
(en)
|
2009-01-12 |
2010-07-15 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
EP3199177A1
(en)
|
2009-10-30 |
2017-08-02 |
GlaxoSmithKline Biologicals S.A. |
Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
|
CN102933267B
(en)
|
2010-05-28 |
2015-05-27 |
泰特里斯在线公司 |
Interactive hybrid asynchronous computer game infrastructure
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20120135025A1
(en)
*
|
2010-10-20 |
2012-05-31 |
Genocea Biosciences, Inc. |
Chlamydia antigens and uses thereof
|
EP2655389A2
(en)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Compounds
|
CN103717235A
(en)
|
2011-06-24 |
2014-04-09 |
埃皮托吉尼西斯有限公司 |
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
|
CN103917245B
(en)
|
2011-09-14 |
2017-06-06 |
葛兰素史密丝克莱恩生物有限公司 |
Method for preparing glycoprotein glycoconjugate
|
CA2854934A1
(en)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
MX2014014067A
(en)
|
2012-05-22 |
2015-02-04 |
Novartis Ag |
Meningococcus serogroup x conjugate.
|
BE1024634B1
(en)
|
2016-04-05 |
2018-05-14 |
Gsk Vaccines S.R.L. |
IMMUNOGENIC COMPOSITIONS
|
CN108514870B
(en)
*
|
2018-04-27 |
2020-02-28 |
湖南大学 |
Hydrotalcite-poly (m-phenylenediamine) composite material and preparation method and application thereof
|